Galactosylhydroxylysine
Galactosylhydroxylysine is released during bone resorption and elevated in subjects with metabolic bone loss. Galactosylhydroxylysine is a sensitive and specific marker of bone resorption. (PMID 10222355 ).
MOLSDF3D-SDFPDBSMILESInChI View 3D Structure
Structure for HMDB00600 (Galactosylhydroxylysine)
C12H24N2O8
324.3276
324.153265754
(2S)-6-amino-2-{N-hydroxy[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino}hexanoic acid
galactosylhydroxylysine
32448-36-5
NCCCC[C@H](N(O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(O)=O
InChI=1S/C12H24N2O8/c13-4-2-1-3-6(12(19)20)14(21)11-10(18)9(17)8(16)7(5-15)22-11/h6-11,15-18,21H,1-5,13H2,(H,19,20)/t6-,7+,8-,9-,10+,11?/m0/s1
RCPOVANIIKXVTB-YPPRVYOWSA-N
This compound belongs to the class of chemical entities known as glycosyl-amino acids. These are compounds consisting of saccharide linked through a glycosyl linkage (O-, N-, or S-) to an amino acid.
Chemical entities
Organic compounds
Organic acids and derivatives
Carboxylic acids and derivatives
Glycosyl-amino acids
Aliphatic heteromonocyclic compounds
Not Available
Detected and Quantified
Not Available
Not Available
Solid
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
Not Available
- Lo Cascio V, Bertoldo F, Gambaro G, Gasperi E, Furlan F, Colapietro F, Lo Cascio C, Campagnola M: Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility. J Bone Miner Res. 1999 Aug;14(8):1420-4. [PubMed:10457275 ]
- Al-Dehaimi AW, Blumsohn A, Eastell R: Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem. 1999 May;45(5):676-81. [PubMed:10222355 ]
Not Available
Not Available
Not Available
Not Available
FDB011652
Not Available
17215976
C05547
PROCOLLAGEN-5-GALACTOSYLOXY-L-LYSINE
Not Available
Not Available
HMDB00600
HMDB00600
5576
22833535
Not Available
Not Available
- Kelleher PC: Urinary excretion of hydroxyproline, hydroxylysine and hydroxylysine glycosides by patients with Pagets disease of bone and carcinoma with metastases in bone. Clin Chim Acta. 1979 Mar 15;92(3):373-9. [PubMed:436278 ]
- Schroder CH, Monnens LA, van Lith-Zanders HM, Trijbels JM, Veerkamp JH: The urinary excretion of total hydroxylysine and its glycosides in normal persons, and in patients suffering from Alports syndrome–contribution of the peptide-bound fraction. Nephron. 1987;47(4):253-7. [PubMed:3696326 ]
- Schroder CH, Langeveld JP, van Raay-Selten BH, Trijbels FJ, de Graaf R, Veerkamp JH, Monnens LA: Urinary excretion of hydroxylysine and its glycosides in normal persons of different ages–influence of maturation. Int J Pediatr Nephrol. 1985 Oct-Dec;6(4):239-44. [PubMed:2419268 ]
- Schroder CH, Monnens LA, van Lith-Zanders HM, Trijbels JM, Veerkamp JH, Langeveld JP: Urinary excretion of hydroxylysine and its glycosides in Alports syndrome and several other glomerulopathies. Nephron. 1986;44(2):103-7. [PubMed:3774073 ]
- Grazioli V, Alfano M, Stenico A, Casari E: Urinary output of hydroxylysine glycosides and pyridinium cross-links in detecting rat bone collagen turnover rate. FEBS Lett. 1996 Jun 17;388(2-3):134-8. [PubMed:8690072 ]
- Marabini R, Sirtori P, Chionna R, Barzizza L, Rubinacci A: Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy. J Endocrinol Invest. 1996 Mar;19(3):154-8. [PubMed:8743280 ]
- Leigh SD, Ju HS, Lundgard R, Daniloff GY, Liu V: Development of an immunoassay for urinary galactosylhydroxylysine. J Immunol Methods. 1998 Nov 1;220(1-2):169-78. [PubMed:9839938 ]
- Sirtori P, Sosio C, Polo RM, Tenni R, Rubinacci A: A comparative study on biochemical markers of bone collagen breakdown in post-menopausal women. Pharmacol Res. 1997 Sep;36(3):229-35. [PubMed:9367668 ]
- LoCascio V, Braga V, Bertoldo F, Bettica P, Pasini AF, Stefani L, Moro L: Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. Clin Endocrinol (Oxf). 1994 Jul;41(1):47-51. [PubMed:8050131 ]
- Al-Dehaimi AW, Blumsohn A, Eastell R: Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem. 1999 May;45(5):676-81. [PubMed:10222355 ]
- Casetta B, Romanello M, Moro L: A rapid and simple method for quantitation of urinary hydroxylysyl glycosides, indicators of collagen turnover, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2000;14(23):2238-41. [PubMed:11114034 ]
- Plebani M, Bernardi D, Meneghetti MF, Ujka F, Zaninotto M: Biological variability in assessing the clinical value of biochemical markers of bone turnover. Clin Chim Acta. 2000 Sep;299(1-2):77-86. [PubMed:10900294 ]
- (). Moro, L., Romanello, M. Galactosylhydroxylysine and bone metabolism: an updated review. Cells and Materials (1997), 7(4), 329-332. .
- (). Kakimoto, Y., Akazawa, Shigenori. Isolation and identification of NG,NG- and NG,N'G-dimethylarginine, N -mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl- -hydroxylysine from human urine. Journal of Biological Chemistry (1970), 245(21), 5751-8. .